AL Amyloidosis | Loosen the Grip

IT’S CHALLENGING TO LOOSEN THE GRIP OF LIGHT CHAIN AMYLOIDOSIS (AL)^1-3

Subscribe for the latest updates on AL.

SIGN UP NOW

Once insoluble amyloid fibrils get a hold of vital organs, they will try to keep them in their grasp forever.

Sign up now to stay up to date about AL.

*Indicates a required field.

FIRST NAME*

LAST NAME*

EMAIL*

PHONE NUMBER*

ZIP CODE*

SPECIALTY*

CONTACT PREFERENCE

Contact Preference

NPI NUMBER

NPI Number

By checking this box and submitting this form, I give Alexion permission to provide promotional information to me or otherwise contact me about Alexion products, services, programs, or other topics that Alexion thinks may interest me.

By clicking Submit, you agree to the Privacy Notice and Terms of Use.

Palladini G, Liedtke M, Zago W, Dolan P, Kinney GG, Gertz MA. The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis. Leuk Lymphoma. 2024;65(8):1068-1078.

Bianchi G, Zhang Y, Comenzo RL. AL amyloidosis: current chemotherapy and immune therapy treatment strategies: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2021;3(4):467-487.

Rizio AA, White MK, D’Souza A, et al. Health-related quality of life instruments for clinical trials in AL amyloidosis: report from the Amyloidosis Forum HRQOL Working Group. Patient Relat Outcome Meas. 2023;14:153-169.

IT’S CHALLENGING TO LOOSEN THE GRIP OF LIGHT CHAIN AMYLOIDOSIS (AL)1-3

SUBSCRIBE FOR THE LATEST UPDATES ON AL

*Indicates a required field.

IT’S CHALLENGING TO LOOSEN THE GRIP OF LIGHT CHAIN AMYLOIDOSIS (AL)^1-3